エックスバイオテック | 10-Q：Q3 2024 四半期報告書

SEC11/14 04:19

XBiotech: Q2 Earnings Snapshot

Yahoo Finance08/13 02:45

エックスバイオテック | 10-Q：Q2 2024 四半期報告書

SEC08/13 02:41

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

Benzinga06/19 01:08

XBiotech Shares Are Trading Higher After the Company Shared Results From the 1-BETTER Study for Advanced Pancreatic Cancer.

Benzinga06/18 23:49

XBiotech Says The Primary Endpoint For The Phase 2 Study Was To Assess The Safety And Tolerability Of Natrunix When Used With The ON+5FU+LV Combination, There Were Fewer Adverse Events Of Any Kind During The 24-Week Treatment Period For The Natrunix...

Benzinga06/18 23:49